ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization)
Latest, FY2024
870
Period ended Dec 31, 2024
Change on a year earlier
+28.3%
678 in FY2023
History
7 years
Since FY2018
Sources
6
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 870 | +28.3% | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2023 | Dec 31, 2023 | 678 | +4.2% | Form 10-K FY2023 (filed 2024-02-21) ↗ |
| FY2022 | Dec 31, 2022 | 651 | +12.8% | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 577 | +59.1% | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 363 | +123.3% | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 163 | +3,216.3% | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | 4.90 | – | Form 10-K FY2019 (filed 2020-02-19) ↗ |
Breakdown
What makes up emgality (galcanezumab) — worldwide revenue ($m) [legacy separate disclosure]
Cite this data
StockData. (2026). Eli Lilly Emgality (galcanezumab) — Worldwide revenue ($M) [legacy separate disclosure] ($M), annual FY2018–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_emgality_ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.